Gilead Sciences, Inc.
NEWS
The biopharma industry remained strong, as demand for COVID-related products skyrocketed. However, some companies are facing layoffs. Here’s a brief overview.
Orna, which began as an academic query at the Massachusetts Institute of Technology (MIT), is a biotechnology company creating fully engineered circular RNA, or O-shaped RNA therapies for the treatment of cancer, autoimmune, and genetic disorders.
Belgium-based Galapagos NV and Foster City, California-based Gilead Sciences halted the ISABELA Phase III clinical trial of ziritaxestat in idiopathic pulmonary fibrosis.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 9, 2021.
Foster City-based Gilead Sciences says its inhaled version of remdesivir, which has been increasingly used in research and practice to combat COVID-19 in hospitalized patients, won’t be available any time soon as it needs more testing in clinical research.
Gilead Sciences has inked a collaboration, option and license deal with Gritstone Oncology to create a vaccine-based immunotherapy as a cure for HIV.
The year is starting to pick up in terms of clinical trial announcements. Here’s a look at last week’s news.
As is typical, the second day of the JP Morgan Annual Healthcare Conference—conducted virtually this year because of the pandemic—had plenty of news from the largest biopharma companies globally.
BioSpace takes a look at some of the announcements that occurred Monday and will continue to update throughout the week.
JOBS
IN THE PRESS